Regeneron will expand its presence in the field of genetic medicines with its new partnership with Mammoth Biosciences to utilize the company's CRISPR-based ultracompact gene editing platform, and the partners will focus on developing in vivo adeno-associated viral vector therapies for cell types and tissues beyond the liver. Mammoth will receive a $5 million upfront payment and a $95 million equity investment in addition to potential milestone payments of up to $370 million for each target developed.